NCT00734734

Safety and Immunogenicity of Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009

A Phase II, Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of FLUAD® Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine, Formulation 2008-2009, When Administered to Elderly Subjects

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Novartis Vaccines · Industry
• Sex: All
• Age: 65 Years
• Healthy volunteers: Accepted

Summary

Trial for annual approval of interpandemic influenza vaccines

Conditions

• Interpandemic Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Seasonal Influenza Vaccine	1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation

Timeline

• Start date: 2008-06-01
• Primary completion: 2008-07-01
• Completion: 2008-07-01
• First posted: 2008-08-14
• Last updated: 2016-01-28
• Results posted: 2016-01-28

Locations

2 sites across 1 country: Italy